Effect of Dosing Frequency on Bisphosphonate Medication Adherence in a Large Longitudinal Cohort of Women

Recker, Robert R.; Gallagher, Rich; MacCosbe, Paul E.
July 2005
Mayo Clinic Proceedings;Jul2005, Vol. 80 Issue 7, p856
Academic Journal
OBJECTIVE: To compare medication adherence with daily vs weekly bisphosphonate dosing for the treatment or prevention of osteoporosis in a broad US retail pharmacy database population. PATIENTS AND METHODS: From October 2002 through September 2003, the medication possession ratio (MPR = days of supply/365 days) was used to assess medication adherence. The MPR was calculated by use of daily and weekly bisphosphonate doses in a longitudinal cohort of patients who received prescriptions from 14,000 US retail pharmacies. Patient prescription information was from a database accessed through NDCHealth in Atlanta, Ga. Adequate adherence was defined as sufficient medication supply to ensure antifracture efficacy (MPR, ≥80%). The effects of patients' age, method of prescription payment, and pattern of past osteoporosis medication use on medication adherence also were evaluated. RESULTS: Of 211,319 study patients, 177,552 (84%) were taking weekly bisphosphonates vs 33,767 (16%) taking the daily prescription. Although significantly more patients taking the weekly compared with the daily bisphosphonates had adequate medication adherence, only about one third of patients in the daily dosing group and fewer than one half in the weekly dosing group achieved adequate adherence. Patients new to bisphosphonates had the worst medication adherence over the year (25.2% for weekly vs 13.2% for daily dosing; P<.001). The highest proportion of adequately adherent patients was among those continuing to take their existing weekly bisphosphonates; however, even in this group, only about 48% exhibited adequate medication adherence. CONCLUSIONS: Once-weekly dosing of bisphosphonates for the treatment or prevention of osteoporosis was associated with better medication adherence than daily dosing during a 1-year observation period. However, even with weekly dosing, adherence remained inadequate in more than one half of patients. These findings indicate that ways to improve medication adherence in the treatment or prevention of osteoporosis are still needed.


Related Articles

  • Efficacy and safety of a bisphosphonate dosed once weekly . Baran, Daniel // Geriatrics;Mar2001, Vol. 56 Issue 3, p28 

    Evaluates the efficacy and safety of biphosphonate alendronate in treating and preventing postmenopausal osteoporosis. Clinical impact of osteoporosis; Steps in a bone remodeling cycle; Evaluation of other antiresorptive agents.

  • Long-Term Tolerability of the Bisphosphonates in Postmenopausal Osteoporosis: A Comparative Review. Kherani, R.B.; Papaioannou, A.; Adachi, J.D. // Drug Safety;Aug2002, Vol. 25 Issue 11, p781 

    Osteoporosis in postmenopausal women is a growing health concern for society. Bisphosphonates have become the mainstay of prevention and treatment with the mounting evidence of their efficacy over the past two decades. This review article examines the use of the etidronate, alendronate and...

  • Osteoporosis in men: an increasingly recognised health problem usually best treated with bisphosphonates. Adis International Limited // Drugs & Therapy Perspectives;Oct2005, Vol. 21 Issue 10, p7 

    Deals with the treatment of osteoporosis in men. Comparison of the incidence of osteoporosis in men with that in women; Causes of osteoporosis in men; Role of bisphosphonates in the treatment of the disease.

  • Alendronate may help prevent steroid-induced osteoporosis in women.  // Geriatrics;Sep98, Vol. 53 Issue 9, p16 

    Focuses on a study conducted in the United States which reported that bisphosponate alendronate sodium (Fosomax) can prevent and treat postmenopausal osteoporosis and osteoporosis caused by corticosteroid therapy in women. Comments from study co-author, Kenneth Saag; Information on...

  • Ending Osteoporosis Therapy Doesn't Increase Fracture Risk.  // RN;Feb2007, Vol. 70 Issue 2, p57 

    The article reports that postmenopausal women with osteoporosis who stopped taking alendronate (Fosamax) experienced a moderate decrease in bone mineral density (BMD) but does not increase their chances of fracture according to a study of 1,099 women. The subjects received 5 to 10 milligrams of...

  • A once-yearly intravenous infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis: COMMENTARY. Johnson, Bruce E. // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p31 

    The article discusses the implications of bisphosphonate usage in prevention of fractures in post menopausal women suffering from osteoporosis. It is mentioned that the results of bisphosphonate infusion is similar to that of oral consumption of bisphosphonates therefore oral treatment would...

  • Ibandronate in the Management of Postmenopausal Osteoporosis. Reginster, Jean-Yves; Hiligsmann, Mickaë; Rabenda, Véronique; Zegels, Brigitte; Neuprez, Audrey; and Olivier Bruyere // Clinical Medicine: Therapeutics;2009, Issue 1, p1409 

    Oral daily and weekly bisphosphonates were considered, for several years, as the mainstay for the treatment of postmenopausal osteoporosis. However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long-term, hence outcomes. This has prompted the...

  • Alendronate reduces fracture risk for women with low T scores.  // Geriatrics;Mar99, Vol. 54 Issue 3, p16 

    Presents information on a study which determined the efficacy of biphosphonate alendronate sodium in preventing bone fractures in postmenopausal women. Methodology; Findings of the study; Conclusion.

  • Risedronate on Two Consecutive Days per Month. Frampton, James E. // Drugs & Aging;2009, Vol. 26 Issue 4, p355 

    â–´Risedronate, an orally administered pyridinal bisphosphonate, is effective in the treatment and prevention of postmenopausal osteoporosis. Efforts to optimize patient adherence and persistence with, and hence the effectiveness of, therapy have led to the development of a 75mg tablet to be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics